Histone methyltransferase SMYD2: ubiquitous regulator of disease
| Autor: | Xin Yi, Xue-Jun Jiang, Ze-Min Fang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Methyltransferase Regulator Nonhistone protein Disease Review Biology Methylation Epigenesis Genetic Histones 03 medical and health sciences Histone H3 0302 clinical medicine Non-histone protein Neoplasms Genetics Humans Molecular Targeted Therapy Enhancer Molecular Biology Genetics (clinical) Variegation Cancer SMYD2 Histone-Lysine N-Methyltransferase Cardiovascular disease 030104 developmental biology Gene Expression Regulation Cardiovascular Diseases 030220 oncology & carcinogenesis Histone methyltransferase Developmental Biology |
| Zdroj: | Clinical Epigenetics |
| ISSN: | 1868-7083 |
| Popis: | SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) and MYND (Myeloid-Nervy-DEAF1) domain-containing protein 2 (SMYD2) is a protein methyltransferase that methylates histone H3 at lysine 4 (H3K4) or lysine 36 (H3K36) and diverse nonhistone proteins. SMYD2 activity is required for normal organismal development and the regulation of a series of pathophysiological processes. Since aberrant SMYD2 expression and its dysfunction are often closely related to multiple diseases, SMYD2 is a promising candidate for the treatment of these diseases, such as cardiovascular disease and cancer. Here, we present an overview of the complex biology of SMYD2 and its family members and their context-dependent nature. Then, we discuss the discovery, structure, inhibitors, roles, and molecular mechanisms of SMYD2 in distinct diseases, with a focus on cardiovascular disease and cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |